

Q1 2021 Interim Report

Audiocast - May 20, 2021 at 10.00 CET



Disclaimer

This presentation, which should be understood to include these slides, their contents or any part of them, any oral presentation, any question or answer session and any written or oral materials discussed or distributed during a company presentation (the "Presentation"), has been prepared by Scandion Oncology A/S ("Scandion Oncology" or the "Company"), to be used solely for a company presentation. The information contained in the Presentation is provided solely for this purpose.


This Presentation does not constitute or form part of, and should not be construed as, any offer, invitation, solicitation or recommendation to purchase, sell or subscribe for any securities in any jurisdiction. The Presentation is intended to present background information on the Company, its business and the industry in which it operates and is not intended to provide complete disclosure. The Company has not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or under any of the relevant securities laws of any state or other jurisdiction of the United States of America.

Certain information contained herein has been obtained from published sources prepared by other parties that the Company has deemed to be relevant and trustworthy. No representation or warranty, express or implied, is made by the Company as to the accuracy, completeness or verification of any information contained in this Presentation. The Company has not made any independent review of information based on public statistics or information from an independent third party regarding the market information that has been provided by such third party, the industry or general publications.

Statements in this Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors as they relate to events and depend on circumstances that will or may occur in the future, whether or not outside the control of the Company. No assurance is given that such forward-looking statements will prove to be correct. Past performance does not guarantee or predict future performance. Moreover, the Company does not – to the extent this is not required by law - undertake any obligation to review, update or confirm expectations or estimates or to release any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this Presentation.

This Presentation as well as any other information provided by or on behalf of the Company in connection herewith shall be governed by Danish law. The courts of Denmark, with the District Court of Copenhagen as the first instance, shall have exclusive jurisdiction to settle any conflict or dispute arising out of or in connection with this Presentation or related matters.

Agenda



Highlights from Q1, 2021

- **January 19:** Scandion Oncology received approval for admission to trading on Nasdaq First North Growth Market Sweden. The first day of trading was February 3, 2021.
 - **January 23:** First 12-patient cohort finalized and green light received from DSMB to continue with the next cohort in the CORIST study
 - **January 28:** Amendment submitted to the DMA regarding the PANTAX study, based on the learnings obtained from the first 12 patient cohort in CORIST
-
- **April 21:** Dr. Richard L. Schilsky was appointed as member of Scandion Oncology's clinical advisory board





“Scandion Oncology is pursuing a major unmet need in cancer treatment, that is prevention or reversal of anticancer drug resistance. The mission of the company is clear and important”



RICHARD L. SCHILSKY, MD, FACP, FSCT, FASCO, former ASCO executive

*Newly appointed member of Scandion Oncology's
Clinical Advisory Board*

Clinical Pipeline

Developing first-in-class medicines for personalized therapy

PROGRAM/ INDICATION	COMPOUND	PHASE	2020	2021	2022	2023
CORIST: Drug resistant metastatic colorectal cancer	SCO-101	Phase II part 1				
		Phase II part 2				
PANTAX: Inoperable or metastatic pancreatic cancer	SCO-101	Phase Ib				
		Phase II				
Biomarker development and clinical validation	SCO-101					

Highlights Q1, 2021

- **CORIST:** First 12-patient cohort finalized and green light received from DSMB to continue with next cohort - **Jan 23, 2021**
- **PANTAX:** Amendment submitted to the DMA based on the learnings obtained from the first 12 patient cohort in CORIST - **Jan 28, 2021**

Upcoming Key Events in 2021

- **CORIST:** Data read-out from part 1 of Phase II is planned for Q2, 2021
- **CORIST:** Initiation of part 2 of Phase II is planned for Q2, 2021
- **PANTAX:** Data read-out from Phase Ib is planned for Q3-Q4, 2021

Financial Update Q1 2021




Key Figures and Selected Financial Posts



TDKK	Q1 2021	Q1 2020	2020
Net sales	0	0	0
Profit/loss before financial items (EBIT)	-9,812	-4,043	-22,888
Profit/loss for the period	-8,761	-3,775	-16,269
Total assets	153,885	16,323	186,408
Cash position	145,216	11,013	5,814
Equity ratio	96%	89%	84%
No. of shares end of the period	32,135,544	19,052,241	32,135,544
Average number of shares	32,135,544	19,052,241	19,610,995
Earnings per share (DKK)	-0.27	-0.20	-0.83

Building the Cancer Drug Resistance Company



Other external expenses

- Progression in two ongoing clinical studies for SCO-101, CORIST and PANTAX

Staff costs

- Strengthening of the organization by the recruitment of key individuals

Strong Cash Position



**Monthly
Cash burn Q1 2021**

**2.2 MDKK
(1.5 MDKK)**


**Cash position
March 31, 2021**

**145.2 MDKK
(11.0 MDKK)**



**Financing of the Company's
operations at least until
after 2022**

Operating Expenses 2019 - 2020 - Q1 2021



Increased effort

Operating expenses will increase going forward due to

- Clinical studies CORIST and PANTAX
- Strengthening of organization

Expected Significant Events 2021


CORIST



Q2 2021

- Data read-out part 1 of Phase II study
- Initiate part 2 of Phase II study

Immuno-oncology



Q2 2021

- Read-out from the preclinical collaboration with Alligator Bioscience AB

PANTAX



Q3-Q4 2021

- Data read-out Phase Ib study
- Initiate application for randomized Phase II study

Financing
secured until at
least after 2022

Why Invest in Scandion Oncology?



Targeting Cancer Drug Resistance

rapid peak sales can be reached given a combination therapy application

Scandion Oncology A/S is a clinical Phase II biotechnology company developing **first-in-class, oral, add-on drugs to revert resistance to existing anti-cancer therapies.**

Targeting USD 37bn chemotherapy market growing at 12% annually

Well-documented Mechanisms of Action

enabling the company to target a wide variety of cancer indications

Lead candidate, SCO-101, currently in clinical Phase II trial (CORIST) targeting metastatic chemotherapy resistant colorectal cancer. Data read-out from part 1 in Q2, 2021

A Phase Ib trial (PANTAX) targeting metastatic pancreatic cancer with expected data read-out in Q3-Q4, 2021

Experienced Leadership

track record of successfully developing biotechnology companies

Proven track-record of preclinical research, clinical trials and deal activities paves the way for **future commercial success whilst reducing execution risk**

Upcoming Events



May 26, 2021	Annual General Meeting
June 2, 2021	Presentation at Redeye Growth Day
August 19, 2021	Half-year report 2021
November 18, 2021	Q3 2021 report
February 17, 2022	Year-end report 2021



Q&A

Investor Relations:

Bo Rode Hansen, President & CEO

Email: ir@scandiononcology.com

Phone: +45 38 10 20 17

**Sign up to Scandion news on
our website:**

www.scandiononcology.com



The Cancer Drug Resistance Company